46.81
0.65 (1.41%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Scholar Rock Holding Corporatio | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | -2.5 |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.00 |
|
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 4.35% |
| 机构持股比例 | 118.63% |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| HALLAL DAVID | - | 48.16 | -36,652 | -1,765,160 |
| WOODS KEITH | - | 48.61 | -48,034 | -2,334,933 |
| 累积净数量 | -84,686 | |||
| 累积净值 ($) | -4,100,093 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 48.39 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| WOODS KEITH | 职员 | 24 Sep 2026 | 处理 (-) | 48,034 | 48.61 | 2,334,933 |
| HALLAL DAVID | 职员 | 21 Sep 2026 | 处理 (-) | 36,652 | 48.16 | 1,765,160 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合